RxDoctor Payments Data

Laurie Jones, NP

Nurse Practitioner · Galax, VANPI 1770784142

Payments from drug & device makers

$1,613in general payments, 2019–2025

Across 81 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$356
  • Otsuka America Pharmaceutical, Inc.$320
  • Johnson & Johnson$270
  • AbbVie$193
  • E.r. Squibb & Sons, L.L.C.$128
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$102
  • plus $244 from 4 others

What the payments were for

  • Food & beverage$1,613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,613 in reported general payments places this provider in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$16,456
Medicare patients
57
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl115$171,429
Invega SustennaPaliperidone Palmitate29$105,996
RexultiBrexpiprazole68$103,754
Abilify AsimtufiiAripiprazole15$80,310
LybalviOlanzapine/Samidorphan Malate11$19,316
Varenicline Tartrate22$7,671
Aripiprazole62$3,775
Divalproex Sodium ErDivalproex Sodium26$2,823
Duloxetine Hcl164$2,820
Buspirone Hcl136$1,920
Oxcarbazepine64$1,905
Hydroxyzine Hcl56$1,205
Mirtazapine74$1,102
Quetiapine Fumarate117$972
Sertraline Hcl151$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii$320$184,06483 claims
AbbVieVraylar$193$171,429115 claims
Johnson & JohnsonInvega Sustenna$270$105,99629 claims
Alkermes, Inc.Lybalvi$356$19,31611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Galax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →